{"id":744697,"date":"2023-04-03T09:18:48","date_gmt":"2023-04-03T13:18:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-receives-u-s-food-and-drug-administration-fda-preliminary-assessment-for-celularitys-investigational-fuse-bone-void-filler-to-be-regulated-as-a-device-by-fdas-center-fo\/"},"modified":"2023-04-03T09:18:48","modified_gmt":"2023-04-03T13:18:48","slug":"celularity-receives-u-s-food-and-drug-administration-fda-preliminary-assessment-for-celularitys-investigational-fuse-bone-void-filler-to-be-regulated-as-a-device-by-fdas-center-fo","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celularity-receives-u-s-food-and-drug-administration-fda-preliminary-assessment-for-celularitys-investigational-fuse-bone-void-filler-to-be-regulated-as-a-device-by-fdas-center-fo\/","title":{"rendered":"Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity\u2019s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA\u2019s Center For Devices And Radiological Health"},"content":{"rendered":"
\n

\n Celularity\u2019s Pre-Request for Designation (Pre-RFD) is based on <\/em>
\n
\n data demonstrating 100 percent biochemical characterization of the product<\/em>\n <\/p>\n

\n Celularity intends to submit 510(k) pre-market notification to <\/em>
\n
\n the FDA Center for Devices and Radiological Health (CDRH) in early 2024<\/em>\n <\/p>\n

\n Today\u2019s FUSE and February\u2019s Investigational Celularity Tendon Wrap Regulatory Updates, Coupled with Celularity\u2019s Growing Middle East Distribution Agreements, Highlight <\/em>
\n
\n Celularity\u2019s Suite of Innovative Biomaterial Products <\/em>\n <\/p>\n

FLORHAM PARK, N.J., April 03, 2023 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (\u201cCelularity\u201d or the \u201cCompany\u201d), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that it received notice from the U.S. Food and Drug Administration (FDA) that the FDA\u2019s Office of Combination Products (OCP) completed its preliminary product classification and jurisdictional assessment of Celularity\u2019s investigational FUSE Bone Void Filler (\u201cFUSE\u201d). FUSE is being developed for use as a passive osteoconductive bone filler in the pelvis, extremities, and posterior-lateral spinal fusion settings as well as other skeletal defects that are not dependent on chemical action to mediate an effect.<\/p>\n

The notification was in response to Celularity\u2019s October 2022 Pre-Request for Designation (Pre-RFD). The OCP reviewed information provided by Celularity in its Pre-RFD, on the basis of which the OCP made a preliminary assessment that it agrees with Celularity\u2019s recommendation that FUSE should be classified as a device regulated by the FDA\u2019s Center for Devices and Radiological Health (CDRH). The OCP preliminary assessment is non-binding. Based on the OCP\u2019s preliminary assessment, Celularity now intends to submit a 510(k) notification for FUSE in early 2024.<\/p>\n

\u201cWe are delighted to receive the FDA\u2019s feedback about the preliminary FUSE product classification and CDRH jurisdiction, on the basis of which we anticipate a 510(k) pre-market notification submission for FUSE in early 2024,\u201d said Robert J. Hariri, M.D., Ph.D., Celularity\u2019s CEO, Chairman and Founder. \u201cCelularity\u2019s unique technology platform is grounded in our use of the post-partum placenta as the source of cells and biomaterials for the development of therapeutics. This creates two independent but complimentary product opportunities in cellular and regenerative medicine. FUSE is an example of how Celularity develops innovative products from the placenta, leveraging our more than 15 biomaterial-related patent families and multiple issued patents. For Celularity, our suite of biomaterial products is a revenue engine that supports continuous new product research and development and enhances the value proposition for our investors.\u201d<\/p>\n

As part of its FUSE pre-RFD submission, Celularity provided data to demonstrate that its proprietary processing steps are designed to remove all cells, cellular debris, residual nucleic acids, cytokines and chemokines, residual hormones, growth factors and other regulators of wound healing, scarring and fibrosis, and well as anti- and pro-inflammatory factors. These processing steps are fully aligned with stringent requirements defined within FDA\u2019s Class II Special Controls Guidance Documents for Industry and FDA Staff.<\/p>\n

FUSE has been designed as an absorbable, biocompatible, and osteoconductive in nature bone void filler. Following placement in the bony void or gap, FUSE resorbs and is replaced with bone during the healing process.<\/p>\n

The global bone void filler market size was valued at $3.2 billion in 2021 and projected to reach $7.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.5 percent from 2022 to 2031, according to a 2022 report by Allied Market Research (AMR). The growth of the market size for global bone void fillers is driven largely by an increase in prevalence of orthopedic diseases, such as osteoarthritis, osteoporosis, scoliosis, bone tumor and bone infection, as well as a surge in geriatric populations, according to the AMR report.<\/p>\n

\n About 510(k) Submission<\/strong>\n <\/p>\n

A 510(k) submission refers to Section 510(k) of the Food, Drug and Cosmetic Act, which requires device manufacturers to notify FDA of their intent to market a medical device at least 90 days in advance. This is known as Pre-market Notification, also called PMN or 510(k). This allows FDA to determine whether the device is equivalent to a device already placed into one of the three classification categories. Thus, “new” devices (not in commercial distribution prior to May 28, 1976) that have not been classified can be properly identified.<\/p>\n

\n Celularity\u2019s Advanced Biomaterial Products<\/strong>\n <\/p>\n

Celularity markets a suite of commercial placenta-derived biomaterial products, including:<\/p>\n